Source: MedPage Today
ORLANDO,
Feb. 27 -- Newly unsealed court documents suggest that AstraZeneca
tried to minimize the risk of diabetes and weight gain associated with
its antipsychotic drug quetiapine (Seroquel), in part by
"cherry-picking" data for publication.
Source: MedPage Today
ORLANDO, Feb. 27 -- Newly unsealed court documents suggest that AstraZeneca tried to minimize the risk of diabetes and weight gain associated with its antipsychotic drug quetiapine (Seroquel), in part by "cherry-picking" data for publication.